The upregulation of PD-1 levels in vaccinated mice supports our strategy to combine the pDom-M/F vaccine with an anti-PD-1 antibody and this can potentially be applied in the clinic as anti-PD-1 antibodies have now been approved for the treatment of recurrent/metastatic HNSCC. preclinical model, antigen-specific T cells were induced by DNA vaccines and increased T … Continue reading The upregulation of PD-1 levels in vaccinated mice supports our strategy to combine the pDom-M/F vaccine with an anti-PD-1 antibody and this can potentially be applied in the clinic as anti-PD-1 antibodies have now been approved for the treatment of recurrent/metastatic HNSCC